Truist Securities Maintains Buy on Neurocrine Biosciences, Raises Price Target to $155

Benzinga Newsdesk www.benzinga.com Positive 87.5%

Neg 0% Neu 0% Pos 87.5%

Truist Securities analyst Danielle Brill maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $140 to $155.